ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1007

Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis

Connor Buechler, Lindsey Wanberg, Nawang Singhe, Cody Rasner, Joseph McGrath, Ziou Jiang, Karen Baker-James and David Pearson, University of Minnesota, Minneapolis, MN

Meeting: ACR Convergence 2024

Keywords: dermatomyositis, Epidemiology, interstitial lung disease, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Dermatomyositis (DM) is associated with significant morbidity and mortality due to disease-related progressive interstitial lung disease (ILD) and malignancy. However, little is known about the risk factors for these outcomes. We aimed to identify the demographic, social, and disease factors associated with DM-related ILD and death.

Methods: This is a retrospective cohort study of adult patients with DM at an academic tertiary referral center. Adults with DM were identified by consistent ICD-10 visit diagnoses between 1/1/2009-1/1/2022. Patient charts were reviewed for confirmation of diagnosis and patient and disease characteristics. DM-related death was defined as that due to DM-associated end-organ damage or medication. Univariate logistic regression controlling for demographics and multivariate logistic regression adjusting for demographics plus variables with p< 0.1 in univariate analyses were performed.

Results: 223 patients with DM were included. The DM-related mortality rate was 8.0% (17/195) and the ILD rate was 26.5% (59/223). Of DM-related deaths, the most common causes were malignancy (41.2%) and ILD (29.4%). Univariate analysis identified presence of antisynthetase antibody, lung symptoms at presentation, male sex, and non-white/BIPOC race as factors that increased odds of developing ILD. Multivariate analysis adjusting for these variables as well as BMI >30 at diagnosis and clinically amyopathic DM (CADM) subtype identified antisynthetase antibody, lung symptoms at presentation, and BMI >30 at presentation as being related to increased odds of ILD [Fig 1]. Univariate analysis identified lung symptoms at presentation, paraneoplastic DM, smoking history, and age > 60 at diagnosis as factors that increased odds of DM-related death. Multivariate analysis adjusting for these variables as well as presence of ILD identified only paraneoplastic DM as being related to increased odds of DM-related death [Fig 2].

Conclusion: While antisynthetase antibodies and respiratory symptoms are known ILD risk factors, our analysis is the first to identify elevated BMI as a risk factor for DM-related ILD, which warrants further investigation particularly as the world’s average BMI increases. Although other social and demographic variables appeared to be predictors of negative outcomes in univariate analyses, their impact disappeared in multivariate analyses, as did the effect of smoking history. Any effect of these variables may have been confounded or mediated by factors both disease-related, such as malignancy in the setting of a smoking history and advanced age, and unrelated to disease such as socioeconomic status, for which we had no data available. Lung symptoms at presentation approached significance as a predictor of DM-related death even when controlling for ILD, suggesting that lung symptoms should prompt close monitoring even absent an ILD diagnosis. Our study also affirms the importance of malignancy workup for new DM patients to predict and prevent DM-related death.

Supporting image 1

Figure 1: Multivariate logistic regression showing odds ratio of developing ILD based on presence or absence of patient or disease characteristics of interest, adjusted for sex, race, age, and additional variables with p-values <0.1 in univariate analyses, which included lung symptoms at presentation, male sex, Black, Indigenous, or person of color (BIPOC) race, BMI>30 at diagnosis, and clinically amyopathic DM (CADM) subtype.

Supporting image 2

Figure 2: Multivariate logistic regression showing odds ratio of dermatomyositis-related death based on presence or absence of patient or disease characteristics of interest, adjusted for sex, race, age, and additional variables with p-values <0.1 in univariate analyses, which included smoking history, age > 60 at diagnosis, and presence of ILD.


Disclosures: C. Buechler: None; L. Wanberg: None; N. Singhe: None; C. Rasner: None; J. McGrath: None; Z. Jiang: None; K. Baker-James: None; D. Pearson: None.

To cite this abstract in AMA style:

Buechler C, Wanberg L, Singhe N, Rasner C, McGrath J, Jiang Z, Baker-James K, Pearson D. Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/demographic-social-and-disease-factors-associated-with-interstitial-lung-disease-and-disease-related-death-in-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/demographic-social-and-disease-factors-associated-with-interstitial-lung-disease-and-disease-related-death-in-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology